Document Classification

Section Type: RESULTS

Text: In contrast, fasting insulin (placebo, 18. 8 + / -8. 9 microU/mL ; benzbromarone, 11. 0 + / -6. 2 microU/mL ; P < 0. 05), homeostasis model assessment of insulin resistance index (placebo, 5. 4 + / -2. 6 ; benzbromarone, 3. 0 + / -1. 7 ; P < 0. 05), and tumor necrosis factor-alpha (placebo, 2. 59 + / -0. 63 pg/mL ; benzbromarone, 2. 14 + / -0. 51 pg/mL ; P < 0. 05) improved after benzbromarone, and the changes in tumor necrosis factor-alpha levels were correlated with reduction of SUA (P < 0. 05).